129 related articles for article (PubMed ID: 20030633)
1. Mode of action considerations in the quantitative assessment of tumour responses in the liver.
Boobis AR
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):173-9. PubMed ID: 20030633
[TBL] [Abstract][Full Text] [Related]
2. Chloroform mode of action: implications for cancer risk assessment.
Golden RJ; Holm SE; Robinson DE; Julkunen PH; Reese EA
Regul Toxicol Pharmacol; 1997 Oct; 26(2):142-55. PubMed ID: 9356278
[TBL] [Abstract][Full Text] [Related]
3. Development of a quantitative model incorporating key events in a hepatotoxic mode of action to predict tumor incidence.
Luke NS; Sams R; DeVito MJ; Conolly RB; El-Masri HA
Toxicol Sci; 2010 May; 115(1):253-66. PubMed ID: 20106946
[TBL] [Abstract][Full Text] [Related]
4. Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform.
Liao KH; Tan YM; Conolly RB; Borghoff SJ; Gargas ML; Andersen ME; Clewell HJ
Risk Anal; 2007 Dec; 27(6):1535-51. PubMed ID: 18093051
[TBL] [Abstract][Full Text] [Related]
5. Adaptive tolerance in mice upon subchronic exposure to chloroform: Increased exhalation and target tissue regeneration.
Anand SS; Philip BK; Palkar PS; Mumtaz MM; Latendresse JR; Mehendale HM
Toxicol Appl Pharmacol; 2006 Jun; 213(3):267-81. PubMed ID: 16630638
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of chloroform by cytochrome P450 2E1 is required for induction of toxicity in the liver, kidney, and nose of male mice.
Constan AA; Sprankle CS; Peters JM; Kedderis GL; Everitt JI; Wong BA; Gonzalez FL; Butterworth BE
Toxicol Appl Pharmacol; 1999 Oct; 160(2):120-6. PubMed ID: 10527910
[TBL] [Abstract][Full Text] [Related]
7. Carcinogenicity and mode of action evaluation for alpha-hexachlorocyclohexane: Implications for human health risk assessment.
Bradley AE; Shoenfelt JL; Durda JL
Regul Toxicol Pharmacol; 2016 Apr; 76():152-73. PubMed ID: 26713892
[TBL] [Abstract][Full Text] [Related]
8. Improvement and validation of a medium-term gpt delta rat model for predicting chemical carcinogenicity and underlying mode of action.
Matsushita K; Kuroda K; Ishii Y; Takasu S; Kijima A; Kawaguchi H; Miyoshi N; Nohmi T; Ogawa K; Nishikawa A; Umemura T
Exp Toxicol Pathol; 2014 Sep; 66(7):313-21. PubMed ID: 24929978
[TBL] [Abstract][Full Text] [Related]
9. A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments.
Butterworth BE; Conolly RB; Morgan KT
Cancer Lett; 1995 Jun; 93(1):129-46. PubMed ID: 7600540
[TBL] [Abstract][Full Text] [Related]
10. Benzo[a]pyrene-induced transcriptomic responses in primary hepatocytes and in vivo liver: toxicokinetics is essential for in vivo-in vitro comparisons.
van Kesteren PC; Zwart PE; Schaap MM; Pronk TE; van Herwijnen MH; Kleinjans JC; Bokkers BG; Godschalk RW; Zeilmaker MJ; van Steeg H; Luijten M
Arch Toxicol; 2013 Mar; 87(3):505-15. PubMed ID: 23052197
[TBL] [Abstract][Full Text] [Related]
11. Biologically based dose response model for hepatic toxicity: a mechanistically based replacement for traditional estimates of noncancer risk.
Conolly RB; Butterworth BE
Toxicol Lett; 1995 Dec; 82-83():901-6. PubMed ID: 8597160
[TBL] [Abstract][Full Text] [Related]
12. Application of an updated physiologically based pharmacokinetic model for chloroform to evaluate CYP2E1-mediated renal toxicity in rats and mice.
Sasso AF; Schlosser PM; Kedderis GL; Genter MB; Snawder JE; Li Z; Rieth S; Lipscomb JC
Toxicol Sci; 2013 Feb; 131(2):360-74. PubMed ID: 23143927
[TBL] [Abstract][Full Text] [Related]
13. Risk assessment of inhaled chloroform based on its mode of action.
Wolf DC; Butterworth BE
Toxicol Pathol; 1997; 25(1):49-52. PubMed ID: 9061851
[TBL] [Abstract][Full Text] [Related]
14. Lessons learned in applying the U.S. EPA proposed cancer guidelines to specific compounds.
Andersen ME; Meek ME; Boorman GA; Brusick DJ; Cohen SM; Dragan YP; Frederick CB; Goodman JI; Hard GC; O'Flaherty EJ; Robinson DE
Toxicol Sci; 2000 Feb; 53(2):159-72. PubMed ID: 10696764
[TBL] [Abstract][Full Text] [Related]
15. Trichloroethylene cancer risk: simplified calculation of PBPK-based MCLs for cytotoxic end points.
Bogen KT; Gold LS
Regul Toxicol Pharmacol; 1997 Feb; 25(1):26-42. PubMed ID: 9056499
[TBL] [Abstract][Full Text] [Related]
16. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
Gaylor DW
Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
[TBL] [Abstract][Full Text] [Related]
17. Concordance of transcriptional and apical benchmark dose levels for conazole-induced liver effects in mice.
Bhat VS; Hester SD; Nesnow S; Eastmond DA
Toxicol Sci; 2013 Nov; 136(1):205-15. PubMed ID: 23970803
[TBL] [Abstract][Full Text] [Related]
18. Bioactivation, toxicokinetics and acute effects of chloroform in Fisher 344 and Osborne Mendel male rats.
Gemma S; Testai E; Chieco P; Vittozzi L
J Appl Toxicol; 2004; 24(3):203-10. PubMed ID: 15211614
[TBL] [Abstract][Full Text] [Related]
19. The inhalation exposure of carbon tetrachloride promote rat liver carcinogenesis in a medium-term liver bioassay.
Tsujimura K; Ichinose F; Hara T; Yamasaki K; Otsuka M; Fukushima S
Toxicol Lett; 2008 Feb; 176(3):207-14. PubMed ID: 18221844
[TBL] [Abstract][Full Text] [Related]
20. Analysis of carcinogenic risk based on mode of drug action.
Fujii T
J Toxicol Sci; 1995 Sep; 20(4):459-61. PubMed ID: 8531241
[No Abstract] [Full Text] [Related]
[Next] [New Search]
